These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11449745)

  • 1. Using cost and financing instruments for economic evaluation of substance abuse treatment services.
    Salomé HJ; French MT
    Recent Dev Alcohol; 2001; 15():253-69. PubMed ID: 11449745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).
    French MT; Dunlap LJ; Zarkin GA; McGeary KA; McLellan AT
    J Subst Abuse Treat; 1997; 14(5):445-55. PubMed ID: 9437614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the economic cost of substance abuse treatment.
    French MT; McGeary KA
    Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financing of substance abuse treatment services.
    Horgan CM; Merrick EL
    Recent Dev Alcohol; 2001; 15():229-52. PubMed ID: 11449744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program.
    Roebuck MC; French MT; McLellan AT
    J Subst Abuse Treat; 2003 Jul; 25(1):51-7. PubMed ID: 14512108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the Treatment Services Review be used to estimate the costs of addiction and ancillary services?
    French MT; Roebuck MC; McLellan AT; Sindelar JL
    J Subst Abuse; 2000; 12(4):341-61. PubMed ID: 11452838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost estimation when time and resources are limited: the Brief DATCAP.
    French MT; Roebuck MC; McLellan AT
    J Subst Abuse Treat; 2004 Oct; 27(3):187-93. PubMed ID: 15501371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP).
    Salomé HJ; French MT; Miller M; McLellan AT
    Drug Alcohol Depend; 2003 Aug; 71(2):195-206. PubMed ID: 12927658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health care reforms and managed care for substance abuse services: findings from eleven case studies.
    French MT; Dunlap LJ; Galinis DN; Rachal JV; Zarkin GA
    J Public Health Policy; 1996; 17(2):181-203. PubMed ID: 8764391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of drug abuse treatment programs: methodology and findings.
    French MT
    Am J Drug Alcohol Abuse; 1995 Feb; 21(1):111-35. PubMed ID: 7762538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.
    Sindelar JL; Jofre-Bonet M; French MT; McLellan AT
    Drug Alcohol Depend; 2004 Jan; 73(1):41-50. PubMed ID: 14687958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organizational and financial issues in the delivery of substance abuse treatment services.
    Horgan CM; Reif S; Ritter GA; Lee MT
    Recent Dev Alcohol; 2001; 15():9-26. PubMed ID: 11449759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of managed care on programs and practices for the treatment of alcohol and drug dependence.
    Steenrod S; Brisson A; McCarty D; Hodgkin D
    Recent Dev Alcohol; 2001; 15():51-71. PubMed ID: 11449757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A research agenda for economic evaluation of substance abuse services.
    French MT; Drummond M
    J Subst Abuse Treat; 2005 Sep; 29(2):125-37. PubMed ID: 16135341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The organization of substance abuse managed care.
    Sosin MR; D'Aunno T
    Recent Dev Alcohol; 2001; 15():27-49. PubMed ID: 11449746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financing strategies for drug abuse treatment programs.
    Zarkin GA; Galinis DN; French MT; Fountain DL; Ingram PW; Guyett JA
    J Subst Abuse Treat; 1995; 12(6):385-99. PubMed ID: 8749723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.